Do Proton Pump Inhibitors Increase Your Risk of Bone Fractures?
Yes. In this meta-analysis of 11 observational studies, people taking proton pump inhibitors had a 30% higher risk of hip fracture (RR 1.30, 95% CI 1.19-1.43), a 56% higher risk of spine fracture (RR 1.56, 95% CI 1.31-1.85), and a 16% higher risk of fracture at any site (RR 1.16, 95% CI 1.04-1.30). Histamine2-receptor antagonists, the older and weaker class of acid suppressant, were not significantly associated with hip fracture (RR 1.10, 95% CI 0.94-1.30).
Dr. Kumar’s Take
This is a synthesis of observational case-control and cohort studies, not randomized trials, so I read it as a consistent signal rather than proof of cause. The authors say plainly that residual confounding cannot be excluded. Even so, the effect held in both men and women and after stratification by duration of use, and the contrast with H2 blockers is informative: the drug class with the stronger acid suppression is the one carrying the fracture association. The plausible mechanism is impaired calcium absorption when stomach acid is reduced. My practical conclusion matches the authors’: if a patient is on a PPI and also carries osteoporotic fracture risk, their skeletal health deserves a closer look.
What the Research Shows
Ten publications reporting 11 studies met eligibility criteria out of a systematic search of MEDLINE, EMBASE, Web of Science, and BIOSIS Previews covering 1970 through October 10, 2010. All 11 were observational, either case-control or cohort, and they primarily evaluated older adults.
To be included, a study had to examine fracture risk attributable to PPIs or H2RAs, include a comparator control group, document medication use before the fracture occurred, and adjust at minimum for age and gender. Where a study reported more than one set of adjustments, the authors used the most adjusted estimate. Eight authors were contacted and all provided additional unpublished data on fracture risk by site and on sub-analyses restricted by duration of medication use.
Study Snapshot
Design: meta-analysis of 11 observational studies (10 publications). Population: primarily older adults. Exposure: most studies defined PPI or H2RA use as current or recent use, assessed either by prospective questioning of subjects or by review of prescription databases; three studies defined exposure as cumulative medication use from prescription databases regardless of timing. Outcomes: hip, spine, and any-site fracture.
Results in Real Numbers
- Hip fracture, PPI users: RR 1.30 (95% CI 1.19-1.43)
- Spine fracture, PPI users: RR 1.56 (95% CI 1.31-1.85)
- Any-site fracture, PPI users: RR 1.16 (95% CI 1.04-1.30)
- Hip fracture, H2RA users: RR 1.10 (95% CI 0.94-1.30), not statistically significant
- By sex: findings were similar in both men and women
- By duration: findings were similar after stratification by duration of use
Safety, Limits, and Caveats
Every study in this analysis was observational, so causation cannot be established. The authors state directly that the possibility of residual confounding cannot be excluded. Confounding by indication is the obvious concern: people prescribed PPIs may differ from non-users in ways that independently affect bone strength and fall risk.
The included studies also varied in how they defined exposure. Some captured current or recent use through subject questioning, others through prescription databases, and three counted cumulative use regardless of when it occurred. That variation matters when interpreting a pooled estimate.
Context on the regulatory side: the FDA published an advisory about possible increased fracture risk with PPIs and recommended no more than three 14-day treatment courses in one year. Additional data were published after that advisory, which is part of why the authors ran this synthesis.
Practical Takeaways
- Assess fracture risk before committing to long-term PPI therapy, particularly in older adults
- Consider further skeletal evaluation for patients taking PPIs who are also at risk for osteoporotic fracture, which is the authors’ own recommendation
- Use the lowest effective dose for the shortest duration that controls symptoms
- Reassess whether the PPI is still needed at regular intervals, and attempt discontinuation when clinically appropriate
- H2-receptor antagonists were not associated with increased hip fracture risk in this analysis, which is worth weighing when an alternative is reasonable
- Discuss calcium and vitamin D status with your clinician if you are on long-term acid suppression
Related Studies and Research
- Proton Pump Inhibitors Therapy and Risk of Clostridium Difficile Infection
- Meta-Analysis: Proton Pump Inhibitors Moderately Increase Risk of Small Intestinal Bacterial Overgrowth
- Pharmacology of Proton Pump Inhibitors
- ACG Clinical Guideline: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
- Episode 25: The Great GERD Mistake - How Medicine Made Heartburn Worse and How to Fix It
FAQs
How might PPIs increase fracture risk?
The proposed mechanism is impaired calcium absorption. PPIs are potent acid suppressants, and stomach acid helps make dietary calcium available for absorption. Calcium absorption and bone mineral density are among the topics the authors flag as central to this question. Because the underlying studies are observational, the mechanism remains a hypothesis rather than something this analysis proves.
Are all fracture sites affected equally?
No. Spine fracture carried the largest increase in this analysis, RR 1.56, compared with RR 1.30 for hip fracture and RR 1.16 for fracture at any site.
Does the risk depend on how long I have been taking a PPI?
The results were similar after the authors stratified by duration of use.
Do H2 blockers carry the same risk?
Not in this analysis. H2-receptor antagonist use was not significantly associated with hip fracture, RR 1.10 with a confidence interval of 0.94 to 1.30 that crosses 1.
Who should be most cautious?
The studies primarily evaluated older adults. The authors recommend that further skeletal evaluation be considered for patients who are taking PPIs and are also at risk for osteoporotic fracture. If that describes you, raise it with your clinician rather than stopping the medication on your own.
Bottom Line
Pooling 11 observational studies, PPI use was associated with a 30% higher risk of hip fracture, a 56% higher risk of spine fracture, and a 16% higher risk of fracture at any site, while H2-receptor antagonists showed no significant association with hip fracture. These are observational data and residual confounding cannot be excluded, but the finding supports judicious PPI use and a closer look at bone health in patients who take these drugs and already carry osteoporotic fracture risk.
